These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 3218657)

  • 1. Vascular renin-angiotensin system in hypertension. New insights into the mechanism of action of angiotensin converting enzyme inhibitors.
    Dzau VJ
    Am J Med; 1988 Apr; 84(4A):4-8. PubMed ID: 3218657
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating versus local renin-angiotensin system in cardiovascular homeostasis.
    Dzau VJ
    Circulation; 1988 Jun; 77(6 Pt 2):I4-13. PubMed ID: 3286045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Renin inhibitors, angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists: relationships between blood pressure responses and effects on the renin-angiotensin system.
    Schalekamp MA; Derkx FH; van den Meiracker AH
    J Hypertens Suppl; 1992 Dec; 10(7):S157-64. PubMed ID: 1291650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of vascular renin for local generation of angiotensins.
    Higashimori K; Gante J; Holzemann G; Inagami T
    Hypertension; 1991 Mar; 17(3):270-7. PubMed ID: 1999357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibition versus blockade of the renin-angiotensin system.
    Brunner HR; Waeber B; Nussberger J
    Am J Med; 1989 Dec; 87(6B):15S-18S. PubMed ID: 2690609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiotensin-converting enzyme in cardiovascular and adrenal tissues and implications for successful blood pressure management.
    Melby JC
    Am J Cardiol; 1992 Apr; 69(10):2C-7C. PubMed ID: 1546636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue renin-angiotensin systems in the heart and vasculature: possible involvement in the cardiovascular actions of converting enzyme inhibitors.
    Unger T; Gohlke P
    Am J Cardiol; 1990 May; 65(19):3I-10I. PubMed ID: 2159693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The tissue renin-angiotensin system: a target for angiotensin-converting enzyme inhibitors.
    Ganten D; Mullins J; Lindpaintner K
    J Hum Hypertens; 1989 Jun; 3 Suppl 1():63-70. PubMed ID: 2674443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Angiotensin converting enzyme inhibition: discrepancy between antihypertensive effect and suppression of enzyme activity.
    Waeber B; Nussberger J; Juillerat L; Brunner HR
    J Cardiovasc Pharmacol; 1989; 14 Suppl 4():S53-9. PubMed ID: 2483430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue renin-angiotensin system: a site of drug action?
    Zimmerman BG; Dunham EW
    Annu Rev Pharmacol Toxicol; 1997; 37():53-69. PubMed ID: 9131246
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of an angiotensin-converting-enzyme inhibitor on the plasma concentration of cytokines and vasoactive molecules in patients with coronary heart disease and hypertension].
    Khadartsev AA; Logatkina AV; Terekhov IV; Bondar SS; Bondar NV
    Ter Arkh; 2017; 89(12):97-102. PubMed ID: 29411767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hemodynamic effects of inhibitors of the renin-angiotensin system.
    Fouad-Tarazi FM
    J Hypertens Suppl; 1994 Jul; 12(2):S25-9. PubMed ID: 7965262
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of angiotensin-converting enzyme inhibitors on tissue renin-angiotensin systems.
    Lee MA; Paul M; Böhm M; Ganten D
    Am J Cardiol; 1992 Oct; 70(10):12C-19C. PubMed ID: 1414888
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypertensive mechanisms and converting enzyme inhibitors.
    Ferrario CM; Jaiswal N; Yamamoto K; Diz DI; Schiavone MT
    Clin Cardiol; 1991 Aug; 14(8 Suppl 4):IV56-62; discussion IV83-90. PubMed ID: 1893643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New angiotensin converting enzyme inhibitors. Their role in the management of hypertension.
    Laragh JH
    Am J Hypertens; 1990 Nov; 3(11):257S-265S. PubMed ID: 2261144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-range safety and protective benefits of angiotensin-converting enzyme inhibitors for hypertension. Do we need more clinical trials?
    Sambhi MP; Gavras H; Robertson JI; Smith WM
    West J Med; 1993 Mar; 158(3):286-94. PubMed ID: 8460511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of tissue renin-angiotensin systems in hypertension and effects of chronic converting-enzyme inhibition.
    Keuneke C; Yacullo R; Metzger R; Hellmann T; Peters J; Ganten D
    Eur Heart J; 1990 May; 11 Suppl D():11-6. PubMed ID: 2163328
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interrupting the renin-angiotensin system: the role of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists in the treatment of hypertension.
    Weber MA
    Am J Hypertens; 1999 Dec; 12(12 Pt 3):189S-194S. PubMed ID: 10619571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sympathetic and renin-angiotensin systems contribute to increased blood pressure in sucrose-fed rats.
    Freitas RR; Lopes KL; Carillo BA; Bergamaschi CT; Carmona AK; Casarini DE; Furukawa L; Heimann JC; Campos RR; Dolnikoff MS
    Am J Hypertens; 2007 Jun; 20(6):692-8. PubMed ID: 17531930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma angiotensin II and the antihypertensive action of angiotensin-converting enzyme inhibition.
    Nussberger J; Waeber B; Brunner HR
    Am J Hypertens; 1989 Apr; 2(4):286-93. PubMed ID: 2650711
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.